Table 4.
Anti-JCV Ab prevalence and antibody index by patients’ treatment.
| n (%) | Naive | IS | IM | KW-H | CLA | CTX | Mx | KW-H | IFN | GA | DMF | FGL | NTZ | KW-H |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JCV+ | 434 (65.3) | 158 (76.0) | 332 (62.4) | KW-H p = 0.002; MW-UIS/IM: p = 0.01 Other p > 0.05 |
30 (73.2) | 41 (78.8) | 87 (75.7) | KW-H p > 0.05 |
234 (63.8) | 58 (68.2) | 10 (45.5) | 27 (81.8) | 3 (12.0) | KW-H p = 0.002; p < 0.05 only for NTZ comparison |
| JCV− | 231 (34.7) | 50 (24.0) | 200 (37.6) | 11 (26.8) | 11 (21.2) | 28 (24.3) | 133 (36.2) | 27 (31.8) | 12 (54.5) | 6 (18.2) | 22 (88.0) | |||
| AI Mean | 1.45 | 1.67 | 1.36 | KW-H p = 0.004 IS/IM: p = 0.0008 MW-U Naive/IS: MW-U p = 0.01 Naive/IM: p = 0.02 |
1.69 | 1.50 | 1.75 | KW-H p > 0.05 | 1.37 | 1.47 | 1.11 | 1.75 | 0.51 | KW-H p < 0.0001 NTZ-GA p = 0.00002; NTZ-IFN p = 0.00002; NTZ-S1P p = 0.000008; other p > 0.05 |
| AI Median | 0.93 | 1.55 | 0.74 | 1.16 | 1.26 | 1.92 | 0.75 | 1.14 | 0.30 | 1.55 | 0.16 | |||
| AI Min | 0.03 | 0.09 | 0.06 | 0.11 | 0.10 | 0.09 | 0.06 | 0.09 | 0.08 | 0.13 | 0.10 | |||
| AI Max | 4.36 | 4.13 | 4.51 | 4.13 | 3.82 | 4.04 | 4.51 | 3.78 | 4.03 | 4.05 | 3.72 | |||
| AI SD | 1.30 | 1.25 | 1.28 | 1.42 | 1.16 | 1.23 | 1.29 | 1.27 | 1.35 | 1.18 | 0.95 |
IS—classical immunosuppressants, IM—immunomodulatory drugs and selective immunosuppressants, IFN—interferon, GA—glatiramer acetate, DMF—dimethyl fumarate, FGL—fingolimod, NTZ—natalizumab, Mx—mitoxantrone, CTX—cyclophosphamide, CLA—cladribine in vials for subcutaneous administration, AI—antibodies index, and SD—standard deviation.